Armata Pharmaceuticals
ARMP
28 hedge funds and large institutions have $2.27M invested in Armata Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
63% more capital invested
Capital invested by funds: $1.4M → $2.27M (+$875K)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0.07% more ownership
Funds ownership: 2.03% → 2.1% (+0.07%)
3% less funds holding
Funds holding: 29 → 28 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$95.6K |
| 2 |
Renaissance Technologies
New York
|
+$6.21K |
| 3 |
MWPCG
Measured Wealth Private Client Group
Portsmouth,
New Hampshire
|
+$2.59K |
| 4 |
BlackRock
New York
|
+$1.94K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$111 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$24.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.49K |
| 3 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
-$2K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$1.9K |
| 5 |
Morgan Stanley
New York
|
-$277 |
ARMP Hedge Fund Activity: Q3 2025 in Review
28 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q3 2025, worth a combined $2.27M — up 63% from $1.4M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ARMP and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $95.6K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $24.9K sold.
- 28 institutional investors held Armata Pharmaceuticals (ARMP) as of Q3 2025, down from 29 in Q2 2025.
- Funds reported $2.27M of Armata Pharmaceuticals stock for Q3 2025, up 63% quarter-over-quarter.
- 2 funds opened new Armata Pharmaceuticals positions in Q3 2025 and 3 closed out, a net change of -1 holder.
- The largest Armata Pharmaceuticals buyer in Q3 2025 was Vanguard Group, an estimated $95.6K added.
- The largest Armata Pharmaceuticals seller in Q3 2025 was Two Sigma Securities, an estimated $24.9K sold.
Based on aggregated 13F filings for Q3 2025.